search
Back to results

IMPACT: A Safety and Feasibility Study of the IOWA Approach Cardiac Ablation System (IMPACT)

Primary Purpose

Paroxysmal Atrial Fibrillation

Status
Completed
Phase
Locations
France
Study Type
Interventional
Intervention
IOWA Approach Cardiac Ablation System
Sponsored by
Farapulse, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Paroxysmal Atrial Fibrillation

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients who are ≥ 18 and ≤ 70 years of age on the day of enrollment.
  2. Diagnosis of paroxysmal atrial fibrillation defined as symptomatic paroxysmal AF with at least two episodes of paroxysmal AF observed within the 12 months preceding inclusion.
  3. Patients are resistant to anti-arrhythmic treatments.
  4. Anteroposterior Left atrial diameter ≤ 5.5 cm as documented by transthoracic echocardiography (TTE) or computed tomography (CT) within 3 months prior to the procedure.
  5. Subject has no contraindications to intraoperative transesophageal echocardiography;
  6. Subject is scheduled to undergo elective on-pump cardiac surgical procedure(s) to be performed including open-heart surgery for one or more of the following:

    • Mitral valve repair or replacement,
    • Aortic valve repair or replacement
    • Tricuspid valve repair or replacement, or
    • Coronary artery bypass procedures
  7. Left ventricular ejection fraction ≥40% as documented by TTE within 12 months prior to the procedure.
  8. Received a standard cardiac work up and is an appropriate candidate for an investigational procedure as determined by trial investigators.
  9. Subject is willing and capable of providing Informed Consent to undergo study procedures and participate in all examinations and follow-ups associated with this clinical trial.

Exclusion Criteria:

  1. Abnormal cardiac and/or epicardial anatomy (such as adhesion, anomalous coronaries, thickened epicardium, etc.) or pericardial reflections on TTE, MRI or CT.
  2. Prior left-sided cardiac ablation.
  3. Prior history of open chest surgery and/or any procedure where the pericardial space was entered or instrumented (pericardiocentesis, catheter mapping and /or ablation).
  4. Patient has a prosthetic heart valve.
  5. Patient has a left atrial appendage device
  6. Prior history of pericarditis or pericarditis within 3 months based on the TTE examination.
  7. Subject is a woman of child bearing age
  8. Prior history of rheumatic fever.
  9. Prior history of medical procedure involving instrumentation of the left atrium (previous ablation, Atrial septal defect) ASD closure, left atrial appendage occlusion)
  10. History of severe chronic gastrointenstinal problems involving the esophagus, stomach and/or untreated acid reflux
  11. History of abnormal bleeding and/or clotting disorder.
  12. Active malignancy or history of treated cancer within 24 months of enrollment.
  13. Clinically significant infection or sepsis.
  14. History of stroke or TIA within prior 6 months
  15. New York heart Association (NYHA) class IIIb or IV congestive heart failure and/or any heart failure hospitalization within 3 months prior to enrollment.
  16. Body mass index > 35.
  17. Estimate glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 or has ever received dialysis.
  18. History of untreated and serious hypotension, bradycardia or chronotropic incompetence.
  19. Any of the following within 3 months of enrollment:

    • Major surgery except for the index procedure
    • Myocardial infarction
    • Unstable angina
    • Percutaneous coronary intervention (e.g., CABG or PTCA)
    • Sudden cardiac death event
    • Left atrial thrombus that has not resolved as shown by TEE (transesophageal echo) or CT
    • Implant of pacemaker, ICD (implantable cardioverter defribillator) or CRT (cardiac resynchronization therapy).
  20. Solid organ or hematologic transplant, or currently being evaluated for an organ transplant
  21. History of pulmonary hypertension with Pulmonary systolic artery pressure >50 mm Hg, severe Chronic Obstructive Pulmonary Disease or restrictive lung disease.
  22. Patients with any other significant uncontrolled or unstable medical condition (such as uncontrolled brady-arrhythmias, ventricular arrhythmias, hyperthyroidism or significant coagulation disorder).
  23. Life expectancy less than one year.
  24. Clinically significant psychological condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.
  25. Enrolled in another cardiac clinical trial that would interfere with this trial.
  26. Life expectancy less than one year.
  27. Clinically significant psychological condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.
  28. Enrolled in another cardiac clinical trial that would interfere with this trial.

Sites / Locations

  • CHU Bordeaux

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

IOWA Approach Cardiac Ablation

Arm Description

Subjects who are treated with the IOWA Approach Cardiac Ablation System for paroxysmal atrial fibrillation.

Outcomes

Primary Outcome Measures

Primary Safety: A Composite Safety Endpoint Consisting of the Subjects That Experience One or More Serious Adverse Events (SAEs) Related to the Investigational Procedure and/or Device Within 30 Days of the Ablation Procedure or Hospital Discharge.
A composite safety endpoint consisting of the proportion of subjects that experience one or more of the following serious adverse events (SAEs) related to the investigational procedure and/or device within 30 days of the PEF (pulsed electric field) ablation procedure or hospital discharge, whichever is later, except as noted below: Cardiac death Stroke and/or transient ischemic attack (TIA) Myocardial infarction (MI) Excessive bleeding Atrio-esophageal fistula Persistent post-surgical phrenic nerve paralysis at 12 months Severe pulmonary vein stenosis (>70%)

Secondary Outcome Measures

Feasbility: Electrical Isolation of Posterior Left Atrium and Pulmonary Veins.
Proportion of subjects that achieve procedural success. Procedural success is defined as the creation of an electrically isolating "box" lesion encompassing the pulmonary veins and posterior left atrium using the study device.

Full Information

First Posted
October 4, 2018
Last Updated
September 18, 2021
Sponsor
Farapulse, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03700372
Brief Title
IMPACT: A Safety and Feasibility Study of the IOWA Approach Cardiac Ablation System
Acronym
IMPACT
Official Title
IMPACT: A Safety and Feasibility Study of the IOWA Approach Cardiac Ablation System
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
December 13, 2017 (Actual)
Primary Completion Date
April 9, 2019 (Actual)
Study Completion Date
March 3, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Farapulse, Inc.

4. Oversight

Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
IMPACT is a prospective, single-arm, multi-center, safety and feasibility study evaluating the IOWA Approach Cardiac Ablation System (FARAPULSE, Inc.) for the treatment of paroxysmal atrial fibrillation.
Detailed Description
Patients with paroxysmal atrial fibrillation scheduled to undergo cardiac surgery will be screened for enrollment per protocol inclusion and exclusion criteria. Enrolled patients will then undergo ablation using the IOWA Approach Cardiac Ablation System (FARAPULSE, Inc.), followed by concomitant cardiac surgery. Subjects will be followed at 7 days, 30 days, 3 months, 6 months and 12 months with a blanking period for recurrent atrial fibrillation or atrial tachycardia of 3 months following the index ablation procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Paroxysmal Atrial Fibrillation

7. Study Design

Primary Purpose
Treatment
Interventional Study Model
Single Group Assignment
Model Description
Patients with paroxysmal atrial fibrillation undergoing cardiac surgery and meeting all protocol inclusion/exclusion criteria will be treated with the IOWA Approach Cardiac Ablation System.
Masking
None (Open Label)
Allocation
N/A
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
IOWA Approach Cardiac Ablation
Arm Type
Experimental
Arm Description
Subjects who are treated with the IOWA Approach Cardiac Ablation System for paroxysmal atrial fibrillation.
Intervention Type
Device
Intervention Name(s)
IOWA Approach Cardiac Ablation System
Intervention Description
Epicardial ablation using the IOWA Approach Cardiac Ablation System
Primary Outcome Measure Information:
Title
Primary Safety: A Composite Safety Endpoint Consisting of the Subjects That Experience One or More Serious Adverse Events (SAEs) Related to the Investigational Procedure and/or Device Within 30 Days of the Ablation Procedure or Hospital Discharge.
Description
A composite safety endpoint consisting of the proportion of subjects that experience one or more of the following serious adverse events (SAEs) related to the investigational procedure and/or device within 30 days of the PEF (pulsed electric field) ablation procedure or hospital discharge, whichever is later, except as noted below: Cardiac death Stroke and/or transient ischemic attack (TIA) Myocardial infarction (MI) Excessive bleeding Atrio-esophageal fistula Persistent post-surgical phrenic nerve paralysis at 12 months Severe pulmonary vein stenosis (>70%)
Time Frame
30 Days
Secondary Outcome Measure Information:
Title
Feasbility: Electrical Isolation of Posterior Left Atrium and Pulmonary Veins.
Description
Proportion of subjects that achieve procedural success. Procedural success is defined as the creation of an electrically isolating "box" lesion encompassing the pulmonary veins and posterior left atrium using the study device.
Time Frame
1 Day (Acute)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients who are ≥ 18 and ≤ 70 years of age on the day of enrollment. Diagnosis of paroxysmal atrial fibrillation defined as symptomatic paroxysmal AF with at least two episodes of paroxysmal AF observed within the 12 months preceding inclusion. Patients are resistant to anti-arrhythmic treatments. Anteroposterior Left atrial diameter ≤ 5.5 cm as documented by transthoracic echocardiography (TTE) or computed tomography (CT) within 3 months prior to the procedure. Subject has no contraindications to intraoperative transesophageal echocardiography; Subject is scheduled to undergo elective on-pump cardiac surgical procedure(s) to be performed including open-heart surgery for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement Tricuspid valve repair or replacement, or Coronary artery bypass procedures Left ventricular ejection fraction ≥40% as documented by TTE within 12 months prior to the procedure. Received a standard cardiac work up and is an appropriate candidate for an investigational procedure as determined by trial investigators. Subject is willing and capable of providing Informed Consent to undergo study procedures and participate in all examinations and follow-ups associated with this clinical trial. Exclusion Criteria: Abnormal cardiac and/or epicardial anatomy (such as adhesion, anomalous coronaries, thickened epicardium, etc.) or pericardial reflections on TTE, MRI or CT. Prior left-sided cardiac ablation. Prior history of open chest surgery and/or any procedure where the pericardial space was entered or instrumented (pericardiocentesis, catheter mapping and /or ablation). Patient has a prosthetic heart valve. Patient has a left atrial appendage device Prior history of pericarditis or pericarditis within 3 months based on the TTE examination. Subject is a woman of child bearing age Prior history of rheumatic fever. Prior history of medical procedure involving instrumentation of the left atrium (previous ablation, Atrial septal defect) ASD closure, left atrial appendage occlusion) History of severe chronic gastrointenstinal problems involving the esophagus, stomach and/or untreated acid reflux History of abnormal bleeding and/or clotting disorder. Active malignancy or history of treated cancer within 24 months of enrollment. Clinically significant infection or sepsis. History of stroke or TIA within prior 6 months New York heart Association (NYHA) class IIIb or IV congestive heart failure and/or any heart failure hospitalization within 3 months prior to enrollment. Body mass index > 35. Estimate glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 or has ever received dialysis. History of untreated and serious hypotension, bradycardia or chronotropic incompetence. Any of the following within 3 months of enrollment: Major surgery except for the index procedure Myocardial infarction Unstable angina Percutaneous coronary intervention (e.g., CABG or PTCA) Sudden cardiac death event Left atrial thrombus that has not resolved as shown by TEE (transesophageal echo) or CT Implant of pacemaker, ICD (implantable cardioverter defribillator) or CRT (cardiac resynchronization therapy). Solid organ or hematologic transplant, or currently being evaluated for an organ transplant History of pulmonary hypertension with Pulmonary systolic artery pressure >50 mm Hg, severe Chronic Obstructive Pulmonary Disease or restrictive lung disease. Patients with any other significant uncontrolled or unstable medical condition (such as uncontrolled brady-arrhythmias, ventricular arrhythmias, hyperthyroidism or significant coagulation disorder). Life expectancy less than one year. Clinically significant psychological condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements. Enrolled in another cardiac clinical trial that would interfere with this trial. Life expectancy less than one year. Clinically significant psychological condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements. Enrolled in another cardiac clinical trial that would interfere with this trial.
Facility Information:
Facility Name
CHU Bordeaux
City
Pessac
ZIP/Postal Code
33604
Country
France

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

IMPACT: A Safety and Feasibility Study of the IOWA Approach Cardiac Ablation System

We'll reach out to this number within 24 hrs